Search
Fucose
go.drugbank.com/drugs/DB15236InvestigationalFucose is under investigation in clinical trial NCT03354533 (Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II).
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
go.drugbank.com/drugs/DB15243Investigational2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).
Ampreloxetine
go.drugbank.com/drugs/DB15348InvestigationalAmpreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).
Lorukafusp alfa
go.drugbank.com/drugs/DB15443InvestigationalLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Fluzoparib
go.drugbank.com/drugs/DB15637InvestigationalFluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1...
Mesmulogene ancovacivec
go.drugbank.com/drugs/DB06584Investigationalwith MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in
Iseganan
go.drugbank.com/drugs/DB16010InvestigationalIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
Vixarelimab
go.drugbank.com/drugs/DB16350InvestigationalVixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Onvansertib
go.drugbank.com/drugs/DB15110InvestigationalOnvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).